Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Frequently asked questions
What sector does Pulmatrix, Inc (PULM) operate in?
Pulmatrix, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pulmatrix, Inc (PULM) current stock price?
As of the latest data, Pulmatrix, Inc stock price is $1.56, with a previous close of $1.51. Pulmatrix, Inc gained $0.05 in the last trading session, representing a 3.28% increase.
What is Pulmatrix, Inc (PULM) current market capitalization?
Pulmatrix, Inc market cap is approximately 5.70 million.
What is Pulmatrix, Inc (PULM) Earnings Per Share (EPS)?
The trailing EPS is -$1.23.
What is Pulmatrix, Inc (PULM) EBITDA?
Pulmatrix, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.17 million.
Does Pulmatrix, Inc (PULM) pay dividends?
No. Pulmatrix, Inc does not pay a dividend.
What is Pulmatrix, Inc (PULM) beta (volatility) score?
Pulmatrix, Inc has a beta of 1.920, suggesting it is more volatile than the market.
